Where should we draw the line between considering pharmaceutical key opinion leaders as thought leaders vs. calling them “influence peddlers”? A recent article published in “The Chronicle of Higher Education” casts aspersions on the entire protocol of co-mingling powerful KOLs, medical doctors and the academic research community within the context of drug development. We disagree…